PET imaging in oncology
References (326)
- et al.
Growth factors rapidly induce expression of the glucose transporter gene
J Biol Chem
(1988) - et al.
Instrumentation of positron emission tomography: Tomographs and data processing and display systems
Semin Nucl Med
(1992) - et al.
An integrated approach to evaluation of the solitary pulmonary nodule
- et al.
The solitary pulmonary nodule: Assessment, diagnosis and management
Chest
(1987) - et al.
Positron emission tomography in lung cancer
Ann Thorac Surg
(1998) - et al.
Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules—potential role in evaluation and management
Chest
(1993) - et al.
Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxy-glucose positron emission tomography (FDG-PET)
J Thorac Cardiovasc Surg
(1995) - et al.
Evaluation of pulmonary lesions with FDG-PET comparison of findings in patients with and without a history of prior malignancy
Chest
(1996) - et al.
Likelihood of malignancy in a solitary pulmonary nodule comparison of bayesian analysis and results of FDG-PET scan
Chest
(1997) - et al.
PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis
Chest
(1995)
Diabetes decreases FDG accumulation in primary lung cancer
Clin Pos Imag
(1999)
TNM staging of lung cancer
A quick reference chart. Chest
(1999)
Staging non-small cell lung cancer by whole-body positron emission tomographic imaging
Ann Thorac Surg
(1995)
18 F-deoxyglucose radiotherapy in lung cancer: High impact in patients with atelectasis
Int J Radiat Oncol Biol Phys
(1999)
Thoracic nodal staging with PET imaging with FDG in patients with bronchogenic carcinoma
Chest
(1995)
Mediastinal lymph node staging of non-small cell lung cancer: A prospective comparison of computed tomography and positron emission tomography
J Thorac Cardiovasc Surg
(1996)
Clinical assessment of therapeutic effects on cancer using 18F-2-fluoro-2-deoxy-D-glucose and positron emission tomography: Preliminary study of lung cancer
Int J Radiat Oncol Biol Phys
(1990)
Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small cell lung cancer: A prospective pilot study
Ann Oncol
(1998)
Positron emission tomography to stage metastatic colorectal carcinoma to liver
Am J Surg
(1996)
Contribution of PET in the diagnosis of recurrent colorectal cancer: Comparison with conventional imaging
Eur J Surg Oncol
(1995)
Flurination with F2. A convenient synthesis of 2-deoxy-2-fluoro-D-glucose
J Org Chem
(1977)
The Metabolism of Tumors
On the origin of cancer cells
Science
(1956)
Enzymology of cancer cells (first part)
New Engl J Med
(1977)
Enzymology of cancer cells (second part)
New Engl J Med
(1977)
Biochemical strategy of cancer cells and the design of chemotherapy. GHA Clowes Memorial Lecture
Cancer Res
(1983)
Molecular events leading to enhanced glucose transport in rous sarcoma virus—transformed cells
Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes
Science
(1987)
Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study
J Nucl Med
(1997)
Overexpression of glucose transporter and increased FDG uptake in pancreatic carcinoma
J Nucl Med
(1997)
Overexpression of glut-1 glucose transporter in human breast cancer: An immunohistochemical study
Cancer
(1993)
Overexpression of glut-1 and glut-3 in stage I non-small cell lung cancer is associated with poor survival
Cancer
(1997)
Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer
J Nucl Med
(1999)
Hexokinase, differentiation and growth rates of transplanted rat tumors
Cancer Res
(1970)
Physiochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues
J Natl Cancer Inst
(1978)
Inhibition of established rat fibrosarcoma growth by the glucose antagonist 2-deoxy-D-glucose
Surgery
(1987)
Glucose-6-phosphatase activity in normal, precancerous and neoplastic tissues
Cancer Res
(1955)
Glucose utilization of cerebral gliomas measured by (18F) fluorodeoxy-glucose and positron emission tomography
Neurology
(1982)
A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): Nontoxic tracer for rapid tumor detection
J Nucl Med
(1980)
Positron emission tomography using (18F) fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool
Invest Radiol
(1987)
Radiopharmaceuticals XXVII. 18F-labled 2-deoxy-2fluoro-D-Glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: Tissue distribution and imaging studies in animals
J Nucl Med
(1977)
Metabolic trapping as a principle of radiopharmaceutical design: Some factors responsible for the biodistribution of (18F)2-deoxy-2-fluoro-D-glucose
J Nucl Med
(1978)
Nuclear Medicine Tomography: Systems and Services
Emission computed tomographic imaging
A high resolution PET scanner for imaging small animals
Continuousslice PENN-PET: A positron tomograph with volume imaging capability
J Nucl Med
(1990)
System specifications: Model 250
(1998)
Imaging in nuclear medicine
Comparison of dual-head coincidence PET vs ring PET in tumor patients
J Nucl Med
(1999)
Comparison of dual-head coincidence gamma camera FDG imaging with FDG-PET in detection of breast cancer and axillary lymph node metastasis
J Nucl Med
(1999)
Cited by (316)
Preparation and quality control of a new porphyrin complex labeled with <sup>45</sup>Ti for PET imaging
2023, Applied Radiation and IsotopesNanodiagnostics and targeted drug delivery: integrated technologies
2023, Nanotechnology Principles in Drug Targeting and DiagnosisBone marrow segmentation and radiomics analysis of [<sup>18</sup>F]FDG PET/CT images for measurable residual disease assessment in multiple myeloma
2022, Computer Methods and Programs in BiomedicinePET/CT Variants and Pitfalls in Head and Neck Cancers Including Thyroid Cancer
2021, Seminars in Nuclear MedicineOutcome of PET-Negative Solid Pulmonary Nodules: A Retrospective Study
2021, Academic RadiologyCitation Excerpt :The Fleischner Society guidelines, for example, recommend a 5-year follow-up period for such subsolid nodules >6 mm. Nodules in the 0.8-3.0 cm range were chosen for inclusion due to the known rate of false-negative PET/CT interpretation for smaller nodules (<0.8 cm), and the higher likelihood of malignancy in pulmonary masses (≥3 cm) (8,14). While small studies have argued for the value of PET/CT in smaller nodules, most clinicians maintain that PET/CT is unreliable for the characterization of small nodules (7,8,15,16).
Copyright © 2000 Published by Elsevier Inc.